Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

References

• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–1833. doi:10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–1545. doi:10.1016/S0140-6736(15)01281-7
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced non-squamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639. doi:10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135. doi:10.1056/NEJMoa1504627
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a Phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–265. doi:10.1016/S0140-6736(16)32517-X
   PubMed Web of Science ®Google Scholar
• Sun X, Roudi R, Dai T, et al. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer. 2019;19:558. doi:10.1186/s12885-019-5701-6
   PubMed Web of Science ®Google Scholar
• Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4:374–378. doi:10.1001/jamaoncol.2017.2925
   PubMed Web of Science ®Google Scholar
• Sonehara K, Tateishi K, Araki T, et al. The role of immune-related adverse events in prognosis and efficacy prediction for patients with non-small cell lung cancer treated with immunotherapy: a retrospective clinical analysis. Oncology. 2021;99:271–279. doi:10.1159/000511999
   PubMed Web of Science ®Google Scholar
• Diem S, Schmid S, Krapf M, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–178. doi:10.1016/j.lungcan.2017.07.024
   PubMed Web of Science ®Google Scholar
• Mezquita L, Auclin E, Ferrara R, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 2018;4:351–357. doi:10.1001/jamaoncol.2017.4771
   PubMed Web of Science ®Google Scholar
• Egami S, Kawazoe H, Hashimoto H, et al. Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study. J Cancer. 2021;12:2105–2112. doi:10.7150/jca.53242
   PubMed Web of Science ®Google Scholar
• Eun Y, Kim IY, Sun JM, et al. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep. 2019;9:14039. doi:10.1038/s41598-019-50574-6
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Liu J, Li S, Zhang S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal. 2019;33:e22964. doi:10.1002/jcla.22964
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819–1830. doi:10.1016/S0140-6736(18)32409-7
   PubMed Web of Science ®Google Scholar
• Geater S, Özgüroğlu M, Zou W, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383:1328–1339. doi:10.1056/NEJMoa1917346
   PubMed Web of Science ®Google Scholar
• Sugisaka J, Toi Y, Taguri M, et al. Relationship between programmed cell death protein ligand 1 expression and immune-related adverse events in non-small-cell lung cancer patients treated with pembrolizumab. JMA J. 2020;3:58–66. doi:10.31662/jmaj.2019-0005
   PubMedGoogle Scholar
• Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119–iv142. doi:10.1093/annonc/mdx225
   PubMed Web of Science ®Google Scholar
• Minami S, Ihara S, Komuta K, et al. Pretreatment lung immune prognostic index is a prognostic marker of chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitor. World J Oncol. 2019;10:35–45. doi:10.14740/wjon1179
   PubMedGoogle Scholar
• Sonehara K, Tateishi K, Komatsu M, et al. Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer. Thorac Cancer. 2020;11:1578–1586. doi:10.1111/1759-7714.13432
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Gong Y, Keegan P, et al. Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer. JAMA Oncol. 2019;5:1481–1485. doi:10.1001/jamaoncol.2019.1747
   PubMed Web of Science ®Google Scholar